Skip to main content

perampanel

Generic: PERAMPANEL·Brand: FYCOMPA, PERAMPANEL

perampanel: developed by 1 company · 2 FDA decisions.

perampanel evidence translation

What we can confirm

What it means

Source-backed records connect perampanel to CPRX; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could perampanel → CPRX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

treatment of certain types of focal onset seizures in adults and children four years of age and older; used in combination with other medications to treat certain types of primary generalized tonic-clonic seizures in adults and children 12 years of age or olderFocal onset seizures and primary generalized tonic-clonic seizures

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
CATALYST PHARMACEUTICALS, INC. (CPRX)
treatment of certain types of focal onset seizures in adults…
Approved
CATALYST PHARMACEUTICALS, INC. (CPRX)
Focal onset seizures and primary generalized tonic-clonic se…
Approved
FDA Decisions2 records
Approval1 INDICATIONS AND USAGE FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial - Onset Seizures FYCOMPA is indicated for the treatment of partial-onset seizures with or without (CPRX)FDA ↗
NDA208277Type 3 - New Dosage FormStandardOralSuspension
Approval1 INDICATIONS AND USAGE FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial - Onset Seizures FYCOMPA is indicated for the treatment of partial-onset seizures with or without (CPRX)FDA ↗
NDA202834Type 1 - New Molecular EntityStandardOralTablet

Frequently asked questions

Who is developing perampanel?

perampanel is being developed by CATALYST PHARMACEUTICALS, INC..

What is perampanel's latest FDA decision?

The most recent tracked FDA decision for perampanel is Approval for 1 INDICATIONS AND USAGE FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial - Onset Seizures FYCOMPA is indicated for the treatment of partial-onset seizures with or without , dated April 29, 2016.